Clinical evidences supporting the Src/c-Abl pathway as potential therapeutic target in amyotrophic lateral sclerosis

Javier Riancho; Francisco J Gil-Bea; David Castanedo-Vazquez; María José Sedano; Mónica Zufiría; Gorka Fernández Garcia de Eulate; Juan José Poza; Adolfo Lopez de Munain

doi:10.1016/j.jns.2018.08.013

Clinical evidences supporting the Src/c-Abl pathway as potential therapeutic target in amyotrophic lateral sclerosis

J Neurol Sci. 2018 Oct 15:393:80-82. doi: 10.1016/j.jns.2018.08.013. Epub 2018 Aug 11.

Authors

Javier Riancho¹, Francisco J Gil-Bea², David Castanedo-Vazquez³, María José Sedano⁴, Mónica Zufiría⁵, Gorka Fernández Garcia de Eulate⁶, Juan José Poza⁷, Adolfo Lopez de Munain⁸

Affiliations

¹ Department of Neurology, Hospital Sierrallana-IDIVAL, Torrelavega, Spain; CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases), Ministry of Economy and Competitiveness, Institute Carlos III, Madrid, Spain. Electronic address: rianchozj@unican.es.
² CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases), Ministry of Economy and Competitiveness, Institute Carlos III, Madrid, Spain; Neurosciences Area, Institute Biodonostia, San Sebastián, Spain.
³ Department of Neurology, Hospital Sierrallana-IDIVAL, Torrelavega, Spain.
⁴ Department of Neurology, Hospital Sierrallana-IDIVAL, Torrelavega, Spain; CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases), Ministry of Economy and Competitiveness, Institute Carlos III, Madrid, Spain.
⁵ Department of Neurology, Hospital Sierrallana-IDIVAL, Torrelavega, Spain; CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases), Ministry of Economy and Competitiveness, Institute Carlos III, Madrid, Spain; Neurosciences Area, Institute Biodonostia, San Sebastián, Spain.
⁶ Department of Neurology, University Hospital Donostia, San Sebastián, Spain.
⁷ CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases), Ministry of Economy and Competitiveness, Institute Carlos III, Madrid, Spain; Department of Neurology, University Hospital Donostia, San Sebastián, Spain.
⁸ CIBERNED (Center for Networked Biomedical Research on Neurodegenerative Diseases), Ministry of Economy and Competitiveness, Institute Carlos III, Madrid, Spain; Neurosciences Area, Institute Biodonostia, San Sebastián, Spain; Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Department of Neurosciences, University of the Basque Country UPV-EHU, San Sebastián, Spain.

PMID: 30125805
DOI: 10.1016/j.jns.2018.08.013

No abstract available

Keywords: ALS; Amyotrophic lateral sclerosis; Fibroblasts; Motor neuron; Src/c-Abl; Treatment.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Amyotrophic Lateral Sclerosis / drug therapy*
Amyotrophic Lateral Sclerosis / enzymology*
Cell Survival / drug effects
Cells, Cultured
Fibroblasts / drug effects
Fibroblasts / enzymology
Humans
Male
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins c-abl / metabolism*
Signal Transduction
Stress, Physiological / drug effects
Sunitinib / therapeutic use*
src-Family Kinases / metabolism*

Substances

Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl
src-Family Kinases
Sunitinib